Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial-Reference-Cited by-同舟云学术

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

Published:2020-12 Issue:12 Volume:21 Page:1661-1672
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Rocconi Rodney P,Grosen Elizabeth A,Ghamande Sharad A,Chan John K,Barve Minal A,Oh Jonathan,Tewari Devansu,Morris Peter C,Stevens Erin E,Bottsford-Miller Justin N,Tang Min,Aaron Phylicia,Stanbery Laura,Horvath Staci,Wallraven Gladice,Bognar Ernest,Manning Luisa,Nemunaitis John,Shanahan David,Slomovitz Brian M,Herzog Thomas J,Monk Bradley J,Coleman Robert L

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial;Markman;J Clin Oncol,2003

2. Exploring and comparing adverse events between PARP inhibitors;LaFargue;Lancet Oncol,2019

3. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial;Coleman;Lancet,2017

4. TAG vaccine: autologous tumor vaccine genetically modified to express GM-CSF and block production of TGFB2;Maples;BioProcess J,2009

5. Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma;Bristow;Cancer,1999

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors;ESMO Open;2024-09

2. The Role of Furin and Its Therapeutic Potential in Cardiovascular Disease Risk;International Journal of Molecular Sciences;2024-08-26

3. Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy;Future Oncology;2024-08-05

4. 3D engineered scaffold for large-scale Vigil immunotherapy production;Scientific Reports;2024-07-05

5. Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group;Frontiers in Oncology;2024-06-04